Connect with us

Hi, what are you looking for?

World News

Moderna expects to price its COVID vaccine at about $130 in the US

Moderna Inc. expects to price its COVID-19 vaccine at around $130 per dose in the US going forward as purchases move to the private sector from the government, the company’s president Stephen Hoge said in an interview on Monday.

“There are different customers negotiating different prices right now, which is why it’s a little bit complicated,” Hoge said ahead of a Congressional hearing run by Democratic US Senator Bernie Sanders on Moderna’s pricing plans.

Moderna previously said it was considering pricing its COVID vaccine in a range of $110 to $130 per dose in the United States, similar to the range Pfizer Inc. said in October it was considering for its rival COVID shots sold in partnership with BioNTech.

Mr. Hoge said the government’s Medicare health plan for seniors pays $70 per dose for the seasonal influenza vaccine. That there were two to three times more hospitalizations and deaths from COVID in the past three months alone than from the flu went into the company’s pricing reasoning, Hoge said.

The Biden Administration has said the pandemic public health emergency will end in May, shifting price negotiations to insurers and other purchasers instead of just the federal government.

Mr. Sanders, chair of the Senate’s powerful Health, Education, Labor and Pensions Committee, has said Moderna should not raise the price of its vaccine because of the government funding it received. He plans to question Moderna Chief Executive Stephane Bancel on the price increase at the hearing on Wednesday.

Mr. Hoge said the company had more than paid back that federal support by selling a similar number of mRNA COVID vaccines as Pfizer to the government for around $3 billion less, and that Moderna had paid to ramp up its vaccine manufacturing itself.

Moderna in February forecast significantly declining 2023 COVID-19 vaccine sales, which reached $18.4 billion in 2022.

Demand for the shots has declined sharply this year due to built up product inventories around the world and increased population immunity from high rates of vaccination and previous infections. — Reuters

    You May Also Like


    1.22 billion people use Instagram every month. That’s a huge number of Instagrammers trying to hit it big on the platform all at the...


    The head of the International Monetary Fund has warned of increased risks to the stability of the financial system after weeks of banking sector...


    Since the rise of online casinos, cybersecurity has become a major concern for both casino operators and players alike. The transactions that go around...


    The Home Office has made next to no progress in tackling criminal fraud during the past five years, despite it having become Britain’s most...

    Disclaimer:, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2023 | All Rights Reserved